Usefulness of semiquantitative FDG-PET in the prediction of brain tumor treatment response to gamma knife radiosurgery

Journal of Computer Assisted Tomography

Volumn 27, Issue 4, 2003, Pages 525-529

  Lee, Jong Kang ^a   Liu, Ren Shyan ^a   Shiang, Hung Ren ^a   Pan, David Hung Chi ^a  

^a NONE

Author keywords

F 18 fluorodeoxyglucose; Gamma knife radiosurgery; Gliomas; Positron emission tomography

Indexed keywords

FORECASTING; MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY;

CORTEXES; F-18 FLUORODEOXYGLUCOSE; FDG PET; FLUORODEOXYGLUCOSE; GAMMA KNIFE RADIOSURGERY; GLIOMA; PARTIAL REMISSION; POST TREATMENT; TREATMENT RESPONSE; WHITE MATTER;

TUMORS;

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN TUMOR; CANCER REGRESSION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE COURSE; FEMALE; GAMMA KNIFE RADIOSURGERY; GLIOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0041704824     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-200307000-00012     Document Type: Article

References (40)

1. Pollock BP, Gorman DA, Schomberg PJ, et al. The Mayo Clinic gamma knife experience: indications and initial results. Mayo Clin Proc. 1999;74:5-13.
2. Kida Y, Kobayashi T, Mori Y. Gamma knife radiosurgery for low-grade astrocytomas: results of long-term follow up. J Neurosurg. 2000;93(suppl 3):42-46.
3. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic too]. Invest Radiol. 1986;22:360-371.
4. Kim CK, Alavi JB, Alavi A, et al. New grading system of cerebral gliomas using positron emission tomography with F-18-fluorodeoxyglucose. J Neurooncol. 1991;10:85-91.
5. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18-fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.
6. Patronas NJ, Di Chiro G, Brooks RA, et al. Work in progress: [F-18] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982;144:885-889.
7. Di Chiro G, Oldfield EH, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR. 1988;150:189-197.
8. Kim EE, Chung SK, Haynie TP, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG-PET. Radiographics. 1992;12:269-279.
9. Doyle WK, Budinger TF, Valk PE, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [F-18] FDG and Rb-82 positron emission tomography. J Comput Assist Tomogr. 1987;11:563-570.
10. Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191-197.
11. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol. 1998;19:407-413.
12. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816-822.
13. Schifter T, Hoffman JM, Hanson MW, et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr. 1993;17:509-516.
14. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer. 1988;62:1074-1078.
15. Barker FG, Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer. 1997;79:115-126.
16. Coleman RE, Hoffman JM, Hanson MW, et al. Clinical application of PET for the evaluation of brain tumors. J Nucl Med. 1991;32:616-622.
17. Daemen BJ, Elsinga PH, Paans AM, et al. Radiation-induced inhibition of tumor growth as monitored by PET using L-[111C]tyrosine and fluorine-18-fluorodeoxyglucose. J Nucl Med. 1992;33:373-379.
18. Blasberg RG. Prediction of brain tumor therapy response by PET. J Neurooncol. 1994;22:281-286.
19. Holzer T, Herholz K, Jeske J, et al. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr. 1993;17:681-687.
20. Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res. 2002;8:971-979.
21. Inoue HK, Hayashi S, Ishihara J, et al. Fractional gamma knife radiosurgery for malignant gliomas: neurologic effects and FDG-PET studies. Stereotact Funct Neurosurg Suppl. 1995;64:249-257.
22. Mogard J, Kihlstrom L, Ericson K, et al. Recurrent tumor vs radiation effects after gamma knife radiosurgery of intracerebral metastases: diagnosis with PET-FDG. J Comput Assist Tomogr. 1994;18:177-181.
23. Rozental JM, Levine RL, Mehta MP, et al. Early changes in tumor metabolism after treatment: the effects of stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 1991;20:1053-1060.
24. Maruyama I, Sadato N, Waki A, et al. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. J Nucl Med. 1999;40:1085-1090.
25. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol. 1993;3:255-268.
26. Pan DHC, Guo WY, Chung WY, et al. Early effects of gamma knife surgery on malignant and benign intracranial tumors. Stereotact Funct Neurosurg. 1995;64(suppl 1):19-31.
27. Sansur CA, Chin LS, Ames JW, et al. Gamma knife radiosurgery for the treatment of brain metastases. Stereotact Funct Neurosurg. 2000;74:37-51.
28. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added [18F]fluoro-2-deoxyglucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
29. Wang JK, Wu LC, Kao T, et al. A PC-based four-dimensional multi-modality medical tomographic image display and analysis system. J Nucl Med. 1997;38(suppl 1):206.
30. Kops ER, Herzog H, Schmid A, et al. Performance characteristics of an eight-ring whole body PET scanner. J Comput Assist Tomogr. 1990;14:437-445.
31. Hustinx R, Alavi A. SPECT and PET imaging of brain tumors. Neuroimaging Clin N Am. 1999;9:751-766.
32. Thiel A, Pietrzyk U, Sturm V, et al. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging co-registration: technical case report. Neurosurgery. 2000;46:232-234.
33. Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurol Oncol. 1992;12:159-165.
34. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization by [18F]-fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
35. Minn H, Joensuu H, Ahonen A, et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo: comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776-1781.
36. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 192;33:325-329.
37. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure the proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and 3H-thymidine uptake. J Nucl Med. 1993;34:414-419.
38. Di Chiro G, Hatazawa J, Katz DA, et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology. 1987;164:521-526.
39. Holthoff VA, Herholz K, Berhold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer. 1993;72:1394-1403.
40. Glantz MJ, Hoffman JM, Coleman RE, et al. Identification of early recurrence of primary central nervous system tumors by [18F] fluorodeoxyglucose positron emission tomography. Ann Neurol. 1991;29:347-355.